Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by Radboud University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Radboud University
ClinicalTrials.gov Identifier:
NCT00184964
First received: September 12, 2005
Last updated: June 3, 2008
Last verified: June 2008
  Purpose

CT-PET image fusion has the potential to differentiate 'tumor' from 'atelectasis' much better than the CT-scan in patients with non-small cell lung cancer who also have atelectasis.

This however has never been validated on a histological level. In this study patients with non small cell lung cancer and atelectasis who are eligible for surgery undergo a CT-scan and a PET-scan prior to surgery.

The resection specimen will be compared to the preoperative imaging.


Condition Intervention
Carcinoma, Non Small Cell Lung
Procedure: CT-scan, PET-scan

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: The Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis With Histological Examination of the Resected Specimen

Resource links provided by NLM:


Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Histological validation of CT-PET image fusion.

Estimated Enrollment: 15
Study Start Date: June 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

-Patients with non small cell lung cancer and atelectasis, who are eligible for surgery.

Exclusion Criteria:

  • age < 18 years
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184964

Contacts
Contact: Dominic A Schinagl, MD +31243614515 d.schinagl@rther.umcn.nl

Locations
Netherlands
Radboud University Nijmegen Medical Centre Recruiting
Nijmegen, Gelderland, Netherlands, 6500HB
Contact: Dominic A Schinagl, MD    +31243614515    d.schinagl@rther.umcn.nl   
Principal Investigator: Dominic A Schinagl, MD         
Sponsors and Collaborators
Radboud University
Investigators
Study Director: Jan Bussink, MD, PhD Radiation oncologist, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00184964     History of Changes
Other Study ID Numbers: 2004/032
Study First Received: September 12, 2005
Last Updated: June 3, 2008
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Additional relevant MeSH terms:
Pulmonary Atelectasis
Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Lung Diseases
Respiratory Tract Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on July 20, 2014